|
Originally published In Press as doi:10.1074/jbc.M204521200 on July 1, 2002
J. Biol. Chem., Vol. 277, Issue 37, 34109-34116, September 13, 2002
Gliadin T Cell Epitope Selection by Tissue Transglutaminase in
Celiac Disease
ROLE OF ENZYME SPECIFICITY AND pH INFLUENCE ON THE
TRANSAMIDATION VERSUS DEAMIDATION REACTIONS*
Burkhard
Fleckenstein ,
Øyvind
Molberg ,
Shuo-Wang
Qiao ,
Dietmar G.
Schmid§,
Florian
von der Mülbe§,
Katja
Elgstøen¶,
Günther
Jung§, and
Ludvig M.
Sollid
From the Institutes of Immunology and
¶ Clinical Biochemistry, Rikshospitalet, University of Oslo,
N-0027 Oslo, Norway and the § Institute of Organic
Chemistry, University of Tübingen, D-72076 Tübingen,
Germany
Received for publication, May 8, 2002, and in revised form, June 19, 2002
 |
ABSTRACT |
Tissue transglutaminase (TG2) can modify proteins
by transamidation or deamidation of specific glutamine residues. TG2
has a major role in the pathogenesis of celiac disease as it is
both the target of disease-specific autoantibodies and generates
deamidated gliadin peptides that are recognized by
CD4+, DQ2-restricted T cells from the celiac lesions.
Capillary electrophoresis with fluorescence-labeled gliadin peptides
was used to separate and quantify deamidated and transamidated
products. In a competition assay, the affinity of TG2 to a set of
overlapping -gliadin peptides was measured and compared with their
recognition by celiac lesion T cells. Peptides differed considerably in
their competition efficiency. Those peptides recognized by intestinal T
cell lines showed marked competition indicating them as excellent
substrates for TG2. The enzyme fine specificity of TG2 was
characterized by synthetic peptide libraries and mass spectrometry.
Residues in positions 1, +1, +2, and +3 relative to the targeted
glutamine residue influenced the enzyme activity, and proline in
position +2 had a particularly positive effect. The characterized
sequence specificity of TG2 explained the variation between peptides as
TG2 substrates indicating that the enzyme is involved in the selection
of gluten T cell epitopes. The enzyme is mainly localized
extracellularly in the small intestine where primary amines as
substrates for the competing transamidation reaction are present. The
deamidation could possibly take place in this compartment as an excess
of primary amines did not completely inhibit deamidation of gluten peptides at pH 7.3. However, lowering of the pH decreased the reaction rate of the TG2-catalyzed transamidation, whereas the rate of
the deamidation reaction was considerably increased. This suggests that the deamidation of gluten peptides by TG2 more likely takes place in slightly acidic environments.
 |
INTRODUCTION |
The food-sensitive enteropathy celiac disease
(CD)1 is a chronic
inflammatory disorder with a multifactorial etiology (1, 2). The
disease is precipitated by dietary wheat gluten and related proteins in
barley and rye. The ingestion of such proteins induces mucosal
lymphocyte infiltration and villus atrophy. Subjects with active
disease have autoantibodies specific for the enzyme tissue
transglutaminase (3). CD shows a strong genetic association with the
genes encoding for HLA-DQ2 and -DQ8 (1). Gluten-reactive CD4+ T cells isolated from the small intestine of CD
patients are almost exclusively restricted by either of these HLA
molecules (4, 5), and activation of such T cells is probably a critical event in the disease development (1). Interestingly, the
gluten-reactive T cells of the celiac lesion predominantly recognize
gluten peptides in which certain glutamines are converted to glutamic
acid by deamidation (6). Evidence indicates that tissue
transglutaminase (TG2) can mediate this deamidation in vivo
(7-9). TG2 is best known for its ability to catalyze an acyl transfer
reaction in which the carboxamide group of a peptide-bound glutamine
residue is the acyl donor and an appropriate primary amine is the acyl acceptor (10). The active site of TG2 comprises a catalytic triad built
by cysteine 277, histidine 335, and aspartic acid 358 (11). In the
first step, a glutamine residue forms a thiol ester with the active
site cysteine, and ammonia is released (acylation). In the following
rate-limiting transamidation step, the acyl group is transferred to the
acyl acceptor amine forming an isopeptide bond (deacylation). However,
the thiol ester bond can be also hydrolyzed, resulting in deamidation
of the bound glutamine. In the literature the deamidation reaction is
described to have a slower rate than the transamidation reaction
(10).
To better understand how TG2 can be involved in formation of gluten T
cell epitopes in CD, we have examined the affinity of various peptides
to TG2, we have characterized the specificity of the enzyme, and we
have studied the propensity of the enzyme to catalyze transamidation
and deamidation reactions. We found that the affinity of various
gliadin peptides to TG2 varies, and the peptides that stimulate T cells
are among those with the highest affinity. The variation in affinity
between the peptides can be explained by the fine specificity of the
enzyme. The ratio of the deamidation to transamidation increased when
pH was lowered beneath neutral pH. Our results suggest that the
specificity of TG2 is involved in selection of gluten T cell epitopes
and that the deamidation reaction of gluten peptides in celiac
disease is taking place in slightly acidic environments.
 |
EXPERIMENTAL PROCEDURES |
Synthesis of Peptides and Peptide Libraries--
Synthetic
peptides and peptide libraries were prepared by multiple solid-phase
peptide synthesis on a robotic system (Syro MultiSynTech, Bochum,
Germany) using Fmoc/O-t-butyl chemistry. Individual peptides were synthesized on 2-chlorotrityl resin (Senn Chemicals AG, Dielsdorf, Switzerland) as described previously (12). For
fluorescein labeling, carboxyfluorescein (3 eq, Sigma) was coupled to
the free N-terminal amino group of the resin-bound, protected peptide
using diisopropylcarbodiimide (5 eq) as coupling reagent. Identity of
peptides was confirmed by electrospray mass spectrometry, and purity
was analyzed by reversed phase-HPLC. Based on the sequence of
the undecapeptide, TSEKSQTPLVT (13), 10 peptide libraries were
synthesized on polystyrene A RAM amide resin (Rapp Polymere,
Tübingen, Germany). In each library one of the amino acid
residues flanking the central glutamine was replaced by a randomized
position (X), carrying all natural amino acids except
cysteine. Randomized positions were introduced by double couplings with
an equimolar mixture of 19 Fmoc-L-amino acids used in an
equimolar ratio with respect to the coupling sites of the resin.
Defined sequence positions were introduced using a 5-fold molar excess
of single Fmoc-L-amino acids. An optimized synthesis and
work-up protocol was used to obtain equimolar mixtures (14) as analyzed
by electrospray mass spectrometry (15).
Preparation of Antigen and Purification of Tissue
Transglutaminase--
The pepsin and trypsin digestion of crude
gliadin and avenin was performed as described previously (8). Human TG2
was expressed as a glutathione S-transferase fusion protein
in Escherichia coli using the vector construct as described
previously (16). Guinea pig TG2 was obtained from Sigma.
Capillary Electrophoresis--
All analyses were done on a
Beckman MDQ capillary electrophoresis system equipped with a
laser-induced fluorescence detector (488 nm). CE was carried out in a
fused-silica capillary (25-cm length, 75-µm inner diameter)
equilibrated by three rinsing steps using 100 mM sodium
hydroxide, water, and electrophoresis buffer (20 p.s.i., 1.5 min each).
Samples were injected by pressure (0.5 p.s.i., 5 s), and
separations were performed at 22 kV at room temperature. All samples
were running from the cathode to the anode. Two forms of CE using
different electrophoresis buffers were applied: standard capillary zone
electrophoresis (CZE) runs were done with 80 mM sodium
borate, pH 9.3; for micellar electrokinetic chromatography (MEKC) 64 mM sodium borate, 20 mM sodium dodecylsulfate, pH 9.3 was used. The fluorescein-labeled peptide QLQPFPQPQLPY (defined
as F- I, corresponding to 9-gliadin-(57-68)), its
deamidated derivative 9-(57-68)E65 (defined as
F- IE), and the F- I-TG2 complex were separated and
quantified by MEKC. The transamidation product of F- I, which is
obtained by using 5-biotinylpentylamine (5-BP) as an acyl acceptor, is
defined as F- I5BP. F- I and F- IE were
separated from F- I5BP by CZE.
Sample Incubation with TG2--
F- I was incubated at the
concentrations indicated with 1 µM TG2 at 37 °C in 100 mM Tris/Cl, 2 mM CaCl2, pH 7.3 except in experiments in which the effect of pH was investigated. In
competition assays different amounts of single unlabeled competitor
peptides or peptic-tryptic digests of gliadin or avenin were added, and incubation was done for 18 min. To quantify deamidation
versus transamidation, 5-BP was titrated as a primary amine,
and samples were incubated for different time periods. In case of CZE,
samples were diluted at least 1:33 by 100 mM Tris/Cl, pH
7.5, 10 mM EDTA. For MEKC, samples were diluted by 64 mM sodium borate, 20 mM SDS, pH 9.3. It was
shown that under both conditions the enzymatic activity of TG2 was shut
off immediately.
Sequence Specificity of Tissue Transglutaminase--
Peptide
libraries (1 mM) and 5-BP were incubated with 0.1 µM TG2 (guinea pig enzyme, Sigma) in 100 mM
Tris/Cl, pH 7.5 at 37 °C (1 mM 5-BP, 2 h; 0.5 mM 5-BP, 1 h; 100-µl total volume). Samples were
desalted by solid-phase extraction using C18 ZipTip
(Millipore GmbH, Eschborn, Germany) and analyzed by direct infusion
ESI-FTICR mass spectrometry on a passively shielded 4.7-T APEXII
ESI-MALDI-FTICR mass spectrometer (Bruker Daltonik, Bremen, Germany).
The software XMASS version 5.0.10 (Bruker Daltonik) was used for data
acquisition and processing. All samples were diluted in a solution of
1% acetic acid in acetonitrile/water (50/50). ESI (Analytica of
Branford, Branford, CT) was performed in the positive ion mode with a
grounded capillary sprayer needle mounted 60° off-axis. No supporting
nebulizer gas was used, and the flow rate was 1 µl/min. Transamidated
reaction products were identified by their typical mass shift of +311.2 atomic mass units (+155.6 atomic mass units for doubly charged peptides) compared with the original peptides in the library. In each
spectrum, the peak intensities of the converted products were divided
by those of the corresponding unconverted peptides in the same sample
to compensate for differences in ionization behavior and the partial
lack of exact equimolar presentation between different peptides
in the library. These ratios were defined as the "transamidation rate."
Gliadin-specific Intestinal T Cells and T Cell
Assays--
Gluten-reactive T cells were generated from intestinal
biopsies of treated adult celiac disease patients as described
elsewhere (9). The establishment of the T cell clones 380 E2, 387 E9, and 430.1.142 specific for the DQ2- -I ( 9-(57-68)E65) epitope has
been described previously (17). T cell proliferation assays were done
as described previously (9) using an HLA-matched Epstein-Barr
virus-transformed B-lymphoblastoid cell line
(irradiated 80 grays) as antigen-presenting cells.
 |
RESULTS |
Separation and Quantification of TG2-catalyzed Reaction Products by
CZE and MEKC--
The synthetic peptides F- I and
F- IE were used to work out separation conditions by CZE.
The deamidated peptide, which carries an extra negative charge, was
base-line separated from F- I and eluted 0.85 min later. Moreover,
the formation of F- IE by incubation of F- I with TG2
was demonstrated by CZE (data not shown). However, as we were also
interested in separating and quantifying covalent F- I-TG2 complexes
(not discussed in this paper), we changed to MEKC, which allowed us to
separate F- I, the enzymatic deamidation product F- IE,
and F- I-TG2 complexes (Fig. 1,
A and B). The identity of F- IE and
F- I-TG2 complexes was confirmed by adding the synthetic peptide and
a chemically labeled fluorescein isothiocyanate-TG2 adduct,
respectively. The second product observed in Fig. 1B is most
probably a double deamidated derivative, defined as
F- IEE. Incubation of F- I with TG2 in the presence of
5-BP led to the expected transamidation product F- I5BP,
which was separated from F- I and deamidated products only by CZE
(Fig. 1C). The identity of the obtained signals was proven by adding streptavidin-coated beads (Dynal). The major reaction product
and a minor by-product were specifically removed, identifying them as
F- I5BP and a double transamidated derivative
F- I2×5BP.

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 1.
A, electropherogram of the
fluorescein-labeled synthetic peptide QLQPFPQPQLPY (defined as F- I)
analyzed by MEKC (10 µM F- I in 100 mM
Tris/Cl, pH 7.3, 2 mM CaCl2, diluted 1:33). No
absorbance was observed from 0 to 4 min. The F- I synthetic product
contained about 10% of the deamidated peptide F- IE,
which could not be separated by preparative HPLC. B,
electropherogram obtained by MEKC after incubation of 10 µM F- I with 1 µM TG2 at 37 °C for 18 min in incubation buffer. C, electropherogram obtained by
CZE after incubation of 10 µM F- I and 200 µM 5-BP with 1 µM TG2 at 37 °C for
2 h (upper curve). Also shown is the electropherogram
of the same sample after incubation with streptavidin-coated beads (Dynabeads M-280
Streptavidin) for 15 min at 25 °C (lower curve). All
samples were diluted 1:33 with the corresponding electrophoresis
buffer. RFU, relative fluorescence units.
|
|
Validation of the CE-based Analysis--
The quantification of
TG2-catalyzed deamidation products by MEKC and the use of the
fluorescence-labeled substrate F- I was first validated by measuring
the deamidation of F- I by TG2 in 100 mM Tris/Cl, pH 7.3, 2 mM Ca2+. Plotting the reaction velocity
V versus [F- I] revealed a
kcat of 21 min 1 and a
Km of 0.17 mM, resulting in a
kcat/Km of 124 min 1 mM 1. Compared with the
parameters obtained in a recent study for the non-labeled peptide
(kcat = 23 min 1,
Km = 0.35 mM) (18), our measured
Km value is slightly lower, whereas
kcat values are identical. The observed kcat/Km value is still in the
order as expected and may partly reflect the fluorescence labeling of
the peptide and different buffers used in both studies.
Competition of Known Gliadin Substrates--
For a further
validation of the CE-based analysis, single unlabeled - and
-gliadin peptides were used to compete with the deamidation of
F- I. These peptides are known as substrates of TG2 as they are
converted to T cell epitopes by specific deamidation of glutamine
residues. The deamidated reaction product F- IE was
quantified by MEKC, and by comparing results with and without competitors we calculated the competition efficiency over a broad concentration range. The calculated IC50 values obtained
from these titration experiments ranged from 50 µM (for
DQ2- -II) to 235 µM (for DQ2- -I) (Fig.
2). As controls, three peptides from ovalbumin, from hen egg lysozyme, and from the mouse -light chain ( 2 (315)-(89-107)A90) were used. These peptides
have not been described as substrates of TG2 and carry only one
(ovalbumin and hen egg lysozyme peptide) or no ( -light chain
peptide) glutamine residues. For all three peptides only a weak
competition 15% was observed at the highest competitor concentration
used (550 µM), and IC50 values were estimated
to be significantly higher than 550 µM.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 2.
IC50 values of gliadin peptides
and control peptides. F- I (10 µM) and TG2 (1 µM) were incubated for 18 min at 37 °C in incubation
buffer with competitor peptides ranging from 0.4 to 500 µM. The deamidated product (F- IE) was
separated and quantified by MEKC, and competition values were
calculated. The deduced IC50 values correspond to the
competitor concentrations leading to a competition of 50%.
|
|
Competition and T Cell Recognition of Overlapping Peptides from
-Gliadin M36999--
The established competition assay and the
validated CE analysis was used to measure competition of a set of 23 20-mer peptides overlapping by 10 residues and covering nearly the
complete sequence of the -gliadin M36999 (19, 20). F- I was used
as reporter peptide, and its deamidation by TG2 was quantified by MEKC.
To limit the number of assays and CE runs, competition of each peptide was measured at a single concentration of 110 µM, a
concentration where the titration curves obtained for the gliadin
peptides showed the highest slope. The -gliadin peptides showed
significant differences in their competition potency ranging from 73%
(M13) to 9% (M4) (Fig. 3A).
Interestingly, a sequence region (M36999 residues 61-140) was
identified in which all peptides showed competitions >56% (M7-M13).
The same set of 20-mer peptides was screened for recognition after TG2
treatment by six gluten-specific, polyclonal intestinal T cell lines
generated from six different celiac disease patients, and the results
are reported in detail elsewhere (21). Although these T cell lines
recognized different numbers of peptides (from one to six) and varied
in their response to the recognized peptides, the six T cell lines
together recognized eight of the 23 -gliadin peptides: M2, M7, M8,
M10, M12, M13, M23, and M24 (Fig. 3A). With the exception of
M23 (46% competition), all these peptides showed competition higher
than 58%, and five reside in the region M36999 (residues
61-140).

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 3.
A, competition data of 20-mer
-gliadin peptides overlapping by 10 residues. 10 µM
F- I and 1 µM TG2 were incubated for 18 min at 37 °C
with each competitor peptide (110 µM).
Samples were analyzed after dilution with electrophoresis buffer by
MEKC. Asterisks indicate those peptides that are recognized
after TG2 treatment by gluten-specific, intestinal T cell lines
generated from celiac disease patients. (N.T., these
peptides were not tested.) B, predicted score of 20-mer
-gliadin peptides as TG2 substrates. Each prediction of a glutamine
as a target for transamidation/deamidation resulted in a value of 1 (bold and underlined Q) or 0.5 (underlined
Q), and the sum of those values was assigned to each
peptide.
|
|
Competition of Peptic-Tryptic Digests of Gliadin and
Avenin--
Subsequently, more heterogeneous mixtures, as a
peptic-tryptic digest of gliadin and avenin, and the known protein
substrate N,N-dimethylcasein (22) were used as
competitors. From these titration experiments (using 10 µM F- I) IC50 values of 94 and 210 µg/ml
were obtained for the peptic-tryptic digest of gliadin and
N,N-dimethylcasein, respectively. For the
peptic-tryptic digest of avenin, an IC50 of at least 2000 µg/ml was estimated.
Sequence Specificity of Tissue Transglutaminase--
The
undecapeptide TSEKSQTPLVT is an acyl donor substrate for TG2 (13). Ten
peptide libraries randomized in positions 5 to 1 and +1 to +5 with
respect to the central glutamine targeted by TG2 (Table
I) were applied in transamidation assays
using guinea pig TG2 and 5-BP as a primary amine. Transamidated
reaction products were identified by ESI-FTICR mass spectrometry, and
"transamidation rates" were determined.
View this table:
[in this window]
[in a new window]
|
Table I
Substrate specificity of guinea pig TG2
Synthetic peptide libraries were used in a transamidation assay, and
the reaction products were characterized by semiquantitative FTICR mass
spectrometry. Positions 5 to +5 indicate the distance between the
X position and the targeted glutamine residue (Q). The same
notation is given on the x axis of Fig. 4. aa, amino acids.
|
|
These experiments allowed us to assess semiquantitatively the influence
of all 19 amino acid residues in the 10 randomized sequence positions
on TG2-catalyzed transamidation as summarized in Table I. In
positions 5, 4, 3, 2, +4, and +5, all amino acids were more or
less equally well accepted by TG2 as all 19 peptides in these libraries
were found to be transamidated in similar amounts. In all other
positions, amino acid residues influenced the observed transamidation
rate. The most pronounced effect was observed for proline: in position
+2, proline showed by far the most supportive effect, and the
transamidated peptide TSEKSQTPLVT represented almost 40% of all
reaction products. Furthermore, hydrophobic residues were tolerated
more than hydrophilic side chains. A completely opposite result was
found for positions +1 and +3, where proline, and also glycine,
quantitatively abolished transamidation. Almost all other residues were
tolerated in position +1, whereas in position +3 mainly hydrophobic
amino acids were preferred compared with hydrophilic and charged
residues. Although no amino acid showed a pronounced effect in position
1, different residues induced different transamidation rates, and
charged side chains decreased transamidation. The variance of all
transamidation rates found for the 19 amino acids in an X
position describes its impact on the sequence specificity of TG2. Thus,
for the investigated undecapeptide, positions +2 and +3 were found as
most important followed by positions 1 and +1 (Fig.
4).

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 4.
Impact of sequence positions relative to the
glutamine in determining the specificity of TG2. Given is the
variance n x2 ( x)2/n(n 1) of
transamidation rates determined for the 19 amino acid residues present
in a randomized position (where x represents the
transamidation rates and n = 19).
|
|
Sequence Specificity of TG2 Explains the Competition Data of the
-Gliadin Peptides--
The data above strongly suggest that the
spacing between the targeted glutamine and C-terminal proline residues
dominates the specificity of TG2, i.e. QxP (where x,
representing a variable amino acid, indicates the distance between Gln
and Pro) strongly supports transamidation, whereas QP and QxxP
abolish it (Table I). These motifs were used to predict targeted
glutamine residues within the -gliadin peptides to explain their
competition data (Fig. 3A). Glutamines within QP or QxxP
were predicted as not targeted. Glutamines that are part of the QxP
motif were predicted as targets, and a value of 1 was assigned to such
peptides. Sequences containing QxPP or QPPx were not found in these
peptides. Glutamines, which are not followed by proline in positions
+1, +2, or +3, were predicted as moderately targeted if at least three
residues in positions 1, +1, +2, or +3 matched those listed under
"+" in Table I. If so, a value of 0.5 was assigned to such
peptides. The sum of the values assigned to a given peptide would then
reflect the number of predicted glutamine residues that can be targeted by TG2. We found that the prediction correlated with the competition data of the overlapping -gliadin peptides (Fig. 3B).
Especially for peptides M7-M13, prediction scores 2.5 were obtained
that correlated with competition values >56%. Also, competition of C-terminal peptides M22-M24 ( 45%) was predicted, although smaller scores were obtained for these peptides. In contrast, for peptides M1
and M6 prediction scores of 2.5 and 3.0 were found, respectively, but
both showed only moderate competition.
Deamidation in the Presence of Primary Amines--
Using CZE, both
TG2-catalyzed deamidation and transamidation of F- I were quantified
in the presence of 5-BP as a primary amine (Fig. 1C).
Incubation of 10 µM F- I with increasing amounts of
5-BP for 2 h resulted, as expected, in an increase of the
transamidated and a decrease of the deamidated product (Fig.
5A). Notably, at an equimolar
ratio between F- I and 5-BP, deamidation was still superior to
transamidation. Both reaction rates became similar at about 50 µM 5-BP. However, significant deamidation of F- I was
measured even at a 20- and 40-fold excess of 5-BP compared with F- I.
The amount of remaining F- I (about 0.5 µM) was
independent of the 5-BP concentration. Increasing the F- I
concentration at a fixed 5-BP concentration resulted in higher amounts
of F- IE (Fig. 5B). At equimolar conditions
(5, 10, 50, and 200 µM F- I and 5-BP), 2.0, 4.0, 14.5, and 19.5 µM F- IE was measured showing
a decrease in the relative amount of F- IE
with increased substrate concentrations (40, 40, 29, and 9.8%). Nevertheless, an excess of 5-BP of 80-fold (for 5 µM
F- I), 40-fold (for 10 µM F- I), 10-fold (for 50 µM F- I), or 5-fold (for 200 µM F- I)
still resulted in significant generation of deamidated peptide.
However, no deamidation was measured for 50 µM F- I and 1000 µM 5-BP.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 5.
Analysis of TG2-mediated deamidation of
F- I in the presence of 5-BP as a primary amine
using human TG2. Deamidated reaction products after a 2-h
incubation at 37 °C were quantified by CZE. A, F- I (10 µM) was incubated with different amounts of 5-BP.
B, incubation of 5, 10, 50, and 200 µM F- I
with 5-BP ranging in concentration from 0 to 1 mM.
|
|
The data obtained from CZE were complemented with functional assays
using three DQ2-restricted intestinal T cell clones (TCCs) specific for
the DQ2- IE-epitope. These TCCs are highly specific for
the deamidated peptide; they do not recognize the native 9-(57-68)
peptide or its transamidated derivative. In control experiments, we
found that these TCCs recognized the free (DQ2- IE) and
labeled peptides (F- IE) with similar sensitivity (data not
shown). As shown for a representative TCC, the T cell proliferation was
not significantly different in samples of 10 µM F- I
tested after incubation with TG2 in the presence of no or 10 µM 5-BP (Fig. 6). However,
decreased proliferation was observed in the presence of higher
concentrations of 5-BP (50 and 400 µM). Even at a 40-fold
excess of 5-BP compared with F- I, proliferation of the three TCCs
clearly exceeded that measured for the background (incubation of 10 µM F- I without TG2).

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 6.
Proliferation of the DQ2-restricted T cell
clone 380 E2 in response to F- IE
measured by [3H]thymidine incorporation. F- I (10 µM) and human TG2 (1 µM) were incubated
with 0, 10, 50, and 400 µM 5-BP at 37 °C for 2 h.
In the sample without 5-BP, 5.5 µM F- IE
was determined. All samples were diluted as indicated on the
x axis.
|
|
pH Dependence of TG2-catalyzed Deamidation and
Transamidation--
TG2 was incubated with F- I and 5-BP in 100 mM Tris/Cl, 2 mM Ca2+ at various pH
values ranging from 7.5 to 5.5. Separation and quantification of the
deamidated (F- IE) and transamidated reaction product
(F- I5BP) by CZE showed that the ratio of the deamidation
to transamidation reaction rates is influenced by pH (Fig.
7). Lowering of the pH resulted in
decreased formation of F- I5BP and increased formation of
F- IE. Determination of initial transamidation and
deamidation reaction rates showed almost a bisection of the
transamidation rate when pH was lowered from pH 7.5 to pH 6.0 (Fig.
8A). In parallel, however, the
deamidation rate rose 10-fold, reaching nearly the velocity of
transamidation. Furthermore, initial transamidation rates were compared
with deamidation rates determined in the absence of 5-BP. In this case
the deamidation rate stayed constant for both pH values (Fig.
8B).

View larger version (7K):
[in this window]
[in a new window]
|
Fig. 7.
pH dependence of the deamidation and
transamidation activity of TG2. 50 µM F- I and 200 µM 5-BP were incubated for 2 h at 37 °C with 1 µM human TG2 in 100 mM Tris/Cl, 2 mM CaCl2 at various pH values ranging from 7.5 to 5.5. Separation and quantification of the deamidated
(F- IE) ( ) and transamidated reaction product
(F- I5BP) ( ) were achieved by CZE.
|
|

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 8.
Initial reaction rates of the transamidation
and deamidation reactions at pH 7.5 and pH 6.0. F- I (50 µM) and human TG2 (1 µM) were incubated
with 5-BP (200 µM, black bars) or without 5-BP
(open bars) in 100 mM Tris/Cl, 2 mM
CaCl2 at 37 °C. Formation of deamidated and
transamidated reaction products at different time points was quantified
by CZE.
|
|
 |
DISCUSSION |
The majority of T cells of the celiac small intestinal lesion
recognize deamidated gluten peptides. This study provides details as to
how the enzyme TG2 is responsible for this deamidation and demonstrates
that the enzyme is directly involved in the selection of gluten T cell
epitopes. Moreover, our results reveal that TG2-catalyzed gluten
deamidation could possibly occur extracellularly as an excess of
primary amines did not completely inhibit deamidation at pH 7.3. However, the deamidation is more likely to take place in a slightly
acidic environment. Lowering of the pH resulted in a dramatic increase
in the ratio of deamidated to transamidated products formed in the
presence of primary amines.
Deamidation of a glutamine side chain adds a negative charge to the
peptide. Capillary electrophoresis, which separates mainly according to
charge, functioned well for fast separation and quantification of educt
and deamidated and transamidated reaction products. All reaction
products of a fluorescein-labeled reporter peptide could be detected
with high specificity and sensitivity with laser-induced fluorescence
detection also in competition assays. This was especially relevant when
heterogeneous competitor samples, like peptic-tryptic digests of
gliadin or avenin, were used. Interestingly, the peptic-tryptic digest
of avenin was found to be a much poorer substrate for TG2 than the
peptic-tryptic digest of gliadin. This is likely related to the
different toxicities of the two cereal proteins for celiac patients (23). A similar conclusion was recently reached in a study by
Vader et al. (24).
We addressed the question of whether TG2 is involved in the selection
of gliadin-derived T cell epitopes. We measured the competition of a
set of overlapping -gliadin peptides and compared these data with
the recognition of the same peptides by intestinal T cell lines
generated from CD patients. We also determined the specificity of TG2.
The latter was analyzed by means of peptide libraries and mass
spectrometry using guinea pig TG2 in a transamidation assay with 5-BP.
Transamidated reaction products differ in mass from their educts by
+311.2 atomic mass units, compared with +1 atomic mass unit for
the deamidation reaction, and were therefore easier to identify when a
peptide library was used as an educt. As the acyl donor substrate
(glutamine-containing peptide) is bound to the enzyme prior to the
primary amine, sequence specificity should be identical in the
deamidation and transamidation reactions. The spacing between the
targeted glutamine and proline in the C-terminal positions +1,+2, and
+3 played a dominating role in the specificity of TG2. Our data
(i.e. TG2 preferred mostly QxP but not QP or QxxP) are in
accordance with a previous report on specificity of guinea pig TG2
where deamidation within synthetic substitution analogs of gliadin
peptides was analyzed by tandem mass spectrometry (24). Unlike the
previous report, we also found an influence of residues in position
1. The determined sequence specificity of TG2 nicely explains the
variation in competition observed between the overlapping -gliadin
peptides. Although these experiments do not directly prove the
deamidation within these peptides, eight peptides were recognized after
TG2 treatment by the T cell lines indicating that they indeed undergo
TG2-catalyzed deamidation. Notably, these peptides were among those
with the highest competition values signifying them as excellent
substrates of TG2. From these results it can be concluded that TG2
itself is participating in epitope selection in CD.
At pH 7.3, TG2-mediated deamidation did occur even at an excess of
primary amines (5-BP). In the small intestine, TG2 is predominantly expressed extracellularly in the subepithelial region just beneath the
basal membrane (7) where the pH is likely around 7.3 and a variety of
primary amines competing for the transamidation reaction are present.
Our data indicate that DQ2-restricted T cell epitopes can be formed by
TG2-catalyzed deamidation in this extracellular compartment in
vivo. However, the ratio of deamidated to transamidated products
was significantly increased when pH was lowered from 7.3. This suggests
that deamidation in the gut is likely to occur in compartments with a
slightly acidic pH. Apart from its extracellular expression, TG2 is
also expressed in the epithelial cells including the brush border (7).
The pH in the proximal small intestine is about pH 6.6 (25), which
should allow a predominant deamidation of peptides in the brush border.
Another possibility is that TG2 is endocytosed and is active during the
initial pH decrease in early endosomes. This could be by endocytosis of
surface immunoglobulin by TG2-specific B cells (26) or by endocytosis
of TG2 expressed in the surface membranes of macrophages and dendritic
cells (27-30). A substantial fraction of the active site of TG2 may be
occupied by gluten peptides in the gut (18), and co-internalized free gluten peptides also could be subjected to deamidation.
Our data demonstrate that the rates of the transamidation and
deamidation reactions are dramatically changed over a narrow pH range
(from pH 6.0 to pH 7.3). The results resemble titration curves of an
acid/base pair around a given pKa value. To
allow the nucleophilic attack on the thiol ester intermediate, the
amine must be unprotonated. As the pKa of lysine
and 5-BP is around 10.5, slight pH changes in the range we observed
would not lead to significant alteration in the ratio of their
protonated and unprotonated -amino group as suggested in an earlier
study to explain the decreased transamidation at low pH (31). Rather we
propose a general base-catalyzed deacylation mechanism for the
transamidation reaction (32). A basic amino acid in TG2 (possibly
histidine 335 of the catalytic triad) removes a proton from the amine
substrate during the rate-limiting deacylation step. Notably, the
pKa of the imidazole group of a histidine in active sites of enzymes is in the range where we observed the pH effect
on the transamidation reaction (33). Lowering of the pH below the
pKa of this base would increase its protonation. Consequently the competing nucleophilic attack by water molecules is
favored, explaining the increased deamidation rate. As the concentration of water molecules is pH-independent, deamidation in the
absence of primary amines is not influenced by a pH shift.
Our data strongly suppose that TG2 is involved in the selection of
epitopes recognized by T cells of the intestinal celiac lesion and
indicate that TG2-catalyzed deamidation occurs in a slightly acidic
environment. To define exactly where this is in the intestinal mucosa
should be the focus of further studies. Detailed insight into the cell
biology and biochemistry of this process may lead to the identification
of new targets for therapy in CD.
 |
ACKNOWLEDGEMENTS |
We thank Profs. Hans Erik Rugstad and Bjørn
Christophersen for giving access to the Beckman MDQ instrument, Nicole
Sessler for excellent technical assistance, and Prof. Charles Greenberg and Dr. Thung-S. Lai for providing the TG2 expression plasmid.
 |
FOOTNOTES |
*
This work was funded by research grants from the Research
Council of Norway, the European Commission (Grants BMH4-CT98-3087, QLRT-2000-00657, and QLGA-CT-2000-51218), and the Deutsche
Forschungsgemeinschaft (SFB 510, Project D4).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.:
47-230-73811; Fax: 47-230-73822; E-mail:
l.m.sollid@labmed.uio.no.
Published, JBC Papers in Press, July 1, 2002, DOI 10.1074/jbc.M204521200
 |
ABBREVIATIONS |
The abbreviations used are:
CD, celiac disease;
TG2, tissue transglutaminase;
5-BP, 5-biotinylpentylamine;
MEKC, micellar electrokinetic chromatography;
CE, capillary electrophoresis;
CZE, capillary zone electrophoresis;
FTICR, Fourier transform ion
cyclotron resonance;
Fmoc, N-(9-fluorenyl)methoxycarbonyl;
HLA, human histocompatibility leukocyte antigen;
HPLC, high performance
liquid chromatography;
ESI, electrospray ionization;
MALDI, matrix-assisted laser desorption ionization;
TCC, T cell
clone.
 |
REFERENCES |
| 1.
|
Sollid, L. M.
(2000)
Annu. Rev. Immunol.
18,
53-81[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Schuppan, D.
(2000)
Gastroenterology
119,
234-242[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Dieterich, W.,
Ehnis, T.,
Bauer, M.,
Donner, P.,
Volta, U.,
Riecken, E. O.,
and Schuppan, D.
(1997)
Nat. Med.
3,
797-801[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Lundin, K. E. A.,
Scott, H.,
Hansen, T.,
Paulsen, G.,
Halstensen, T. S.,
Fausa, O.,
Thorsby, E.,
and Sollid, L. M.
(1993)
J. Exp. Med.
178,
187-196[Abstract/Free Full Text]
|
| 5.
|
Lundin, K. E. A.,
Scott, H.,
Fausa, O.,
Thorsby, E.,
and Sollid, L. M.
(1994)
Hum. Immunol.
41,
285-291[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Sjöström, H.,
Lundin, K. E. A.,
Molberg, Ø.,
Körner, R.,
McAdam, S. N.,
Anthonsen, D.,
Quarsten, H.,
Noren, O.,
Roepstorff, P.,
Thorsby, E.,
and Sollid, L. M.
(1998)
Scand. J. Immunol.
48,
111-115[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Molberg, Ø.,
McAdam, S. N.,
Körner, R.,
Quarsten, H.,
Kristiansen, C.,
Madsen, L.,
Fugger, L.,
Scott, H.,
Noren, O.,
Roepstorff, P.,
Lundin, K. E. A.,
Sjöström, H.,
and Sollid, L. M.
(1998)
Nat. Med.
4,
713-717[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
van de Wal, Y.,
Kooy, Y.,
van Veelen, P.,
Pena, S.,
Mearin, L.,
Papadopoulos, G.,
and Koning, F.
(1998)
J. Immunol.
161,
1585-1588[Abstract/Free Full Text]
|
| 9.
|
Molberg, Ø.,
McAdam, S.,
Lundin, K. E. A.,
Kristiansen, C.,
Arentz-Hansen, H.,
Kett, K.,
and Sollid, L. M.
(2001)
Eur. J. Immunol.
31,
1317-1323[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Folk, J. E.
(1983)
Adv. Enzymol. Relat. Areas Mol. Biol.
54,
1-56[Medline]
[Order article via Infotrieve]
|
| 11.
|
Liu, S.,
Cerione, R. A.,
and Clardy, J.
(2002)
Proc. Natl. Acad. Sci. U. S. A.
99,
2743-2747[Abstract/Free Full Text]
|
| 12.
|
Jung, G.,
and Beck-Sickinger, A. G.
(1992)
Angew. Chem. Int. Ed. Engl.
31,
367-383[CrossRef]
|
| 13.
|
Pucci, P.,
Malorni, A.,
Marino, G.,
Metafora, S.,
Esposito, C.,
and Porta, R.
(1988)
Biochem. Biophys. Res. Commun.
154,
735-740[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Wiesmüller, K.-H.,
Feiertag, S.,
Fleckenstein, B.,
Kienle, S.,
Stoll, D.,
Herrmann, M.,
and Jung, G.
(1996)
in
Combinatorial Peptide and Nonpeptide Libraries
(Jung, G., ed)
, pp. 203-246, Verlag Chemie, Weinheim, Germany
|
| 15.
|
Metzger, J. W.,
Kempter, C.,
Wiesmüller, K. H.,
and Jung, G.
(1994)
Anal. Biochem.
219,
261-277[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Lai, T. S.,
Slaughter, T. F.,
Koropchak, C. M.,
Haroon, Z. A.,
and Greenberg, C. S.
(1996)
J. Biol. Chem.
271,
31191-31195[Abstract/Free Full Text]
|
| 17.
|
Arentz-Hansen, H.,
Körner, R.,
Molberg, Ø.,
Quarsten, H.,
Vader, W.,
Kooy, Y. M.,
Lundin, K. E. A.,
Koning, F.,
Roepstorff, P.,
Sollid, L. M.,
and McAdam, S. N.
(2000)
J. Exp. Med.
191,
603-612[Abstract/Free Full Text]
|
| 18.
|
Piper, J. L.,
Gray, G. M.,
and Khosla, C.
(2002)
Biochemistry
41,
386-393[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Scheets, K.,
and Hedgcoth, C.
(1988)
Plant Sci.
57,
141-150
|
| 20.
|
Osman, A. A.,
Gunnel, T.,
Dietl, A.,
Uhlig, H. H.,
Amin, M.,
Fleckenstein, B.,
Richter, T.,
and Mothes, T.
(2000)
Clin. Exp. Immunol.
121,
248-254[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
| Arentz-Hansen, H., McAdam, S. N., Molberg, Ø., Fleckenstein, B.,
Lundin, K. E. A., Jörgensen, T. J. D., Jung, G.,
Roepstorff, P., and Sollid, L. M. (2002)
Gastroenterology, in press
|
| 22.
|
Slaughter, T. F.,
Achyuthan, K. E.,
Lai, T. S.,
and Greenberg, C. S.
(1992)
Anal. Biochem.
205,
166-171[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Janatuinen, E. K.,
Kemppainen, T. A.,
Pikkarainen, P. H.,
Holm, K. H.,
Kosma, V. M.,
Uusitupa, M. I.,
Mäki, M.,
and Julkunen, R. J.
(2000)
Gut
46,
327-331[Abstract/Free Full Text]
|
| 24.
|
Vader, L. W.,
de Ru, A.,
van der Wal, Y.,
Kooy, Y. M.,
Benckhuijsen, W.,
Mearin, M. L.,
Drijfhout, J. W.,
van Veelen, P.,
and Koning, F.
(2002)
J. Exp. Med.
195,
643-649[Abstract/Free Full Text]
|
| 25.
|
Evans, D. F.,
Pye, G.,
Bramley, R.,
Clark, A. G.,
Dyson, T. J.,
and Hardcastle, J. D.
(1988)
Gut
29,
1035-1041[Abstract/Free Full Text]
|
| 26.
|
Sollid, L. M.,
Molberg, Ø.,
McAdam, S.,
and Lundin, K. E. A.
(1997)
Gut
41,
851-852[Free Full Text]
|
| 27.
|
Murtaugh, M. P.,
Arend, W. P.,
and Davies, P. J.
(1984)
J. Exp. Med.
159,
114-125[Abstract/Free Full Text]
|
| 28.
|
Le Naour, F.,
Hohenkirk, L.,
Grolleau, A.,
Misek, D. E.,
Lescure, P.,
Geiger, J. D.,
Hanash, S.,
and Beretta, L.
(2001)
J. Biol. Chem.
276,
17920-17931[Abstract/Free Full Text]
|
| 29.
|
Akimov, S. S.,
Krylov, D.,
Fleischman, L. F.,
and Belkin, A. M.
(2000)
J. Cell Biol.
148,
825-838[Abstract/Free Full Text]
|
| 30.
|
Akimov, S. S.,
and Belkin, A. M.
(2001)
Blood
98,
1567-1576[Abstract/Free Full Text]
|
| 31.
|
Mycek, M. J.,
and Waelsch, H.
(1960)
J. Biol. Chem.
235,
3513-3517[Free Full Text]
|
| 32.
|
Leblanc, A.,
Gravel, C.,
Labelle, J.,
and Keillor, J. W.
(2001)
Biochemistry
40,
8335-8342[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Liu, T.,
Ryan, M.,
Dahlquist, F. W.,
and Griffith, O. H.
(1997)
Protein Sci.
6,
1937-1944[Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. L. de Kauwe, Z. Chen, R. P. Anderson, C. L. Keech, J. D. Price, O. Wijburg, D. C. Jackson, J. Ladhams, J. Allison, and J. McCluskey
Resistance to Celiac Disease in Humanized HLA-DR3-DQ2-Transgenic Mice Expressing Specific Anti-Gliadin CD4+ T Cells
J. Immunol.,
June 15, 2009;
182(12):
7440 - 7450.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Tunheim, K. W. Schjetne, I. B. Rasmussen, L. M. Sollid, I. Sandlie, and B. Bogen
Recombinant antibodies for delivery of antigen: a single loop between {beta}-strands in the constant region can accommodate long, complex and tandem T cell epitopes
Int. Immunol.,
March 1, 2008;
20(3):
295 - 306.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Sugimura, M. Hosono, F. Wada, T. Yoshimura, M. Maki, and K. Hitomi
Screening for the Preferred Substrate Sequence of Transglutaminase Using a Phage-displayed Peptide Library: IDENTIFICATION OF PEPTIDE SUBSTRATES FOR TGASE 2 AND FACTOR XIIIA
J. Biol. Chem.,
June 30, 2006;
281(26):
17699 - 17706.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W Dieterich, B Esslinger, D Trapp, E Hahn, T Huff, W Seilmeier, H Wieser, and D Schuppan
Cross linking to tissue transglutaminase and collagen favours gliadin toxicity in coeliac disease
Gut,
April 1, 2006;
55(4):
478 - 484.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-W. Qiao, E. Bergseng, O. Molberg, G. Jung, B. Fleckenstein, and L. M. Sollid
Refining the Rules of Gliadin T Cell Epitope Binding to the Disease-Associated DQ2 Molecule in Celiac Disease: Importance of Proline Spacing and Glutamine Deamidation
J. Immunol.,
July 1, 2005;
175(1):
254 - 261.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Bergseng, J. Xia, C.-Y. Kim, C. Khosla, and L. M. Sollid
Main Chain Hydrogen Bond Interactions in the Binding of Proline-rich Gluten Peptides to the Celiac Disease-associated HLA-DQ2 Molecule
J. Biol. Chem.,
June 10, 2005;
280(23):
21791 - 21796.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Y. Chae, J.-H. Kim, W.-J. Park, Y.-G. Kim, H.-Y. Yun, N. S. Kwon, M.-J. Im, and K. J. Baek
Distinct pH Modulation for Dual Function of G{alpha}h (Transglutaminase II)
J. Biochem.,
March 1, 2005;
137(3):
407 - 413.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-W. Qiao, J. Piper, G. Haraldsen, I. Oynebraten, B. Fleckenstein, O. Molberg, C. Khosla, and L. M. Sollid
Tissue Transglutaminase-Mediated Formation and Cleavage of Histamine-Gliadin Complexes: Biological Effects and Implications for Celiac Disease
J. Immunol.,
February 1, 2005;
174(3):
1657 - 1663.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Schwertz, F. Kahlenberg, U. Sack, T. Richter, M. Stern, K. Conrad, K.-P. Zimmer, and T. Mothes
Serologic Assay Based on Gliadin-Related Nonapeptides as a Highly Sensitive and Specific Diagnostic Aid in Celiac Disease
Clin. Chem.,
December 1, 2004;
50(12):
2370 - 2375.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E H A Spaenij-Dekking, E M C Kooy-Winkelaar, W F Nieuwenhuizen, J W Drijfhout, and F Koning
A novel and sensitive method for the detection of T cell stimulatory epitopes of {alpha}/{beta}- and {gamma}-gliadin
Gut,
September 1, 2004;
53(9):
1267 - 1273.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-W. Qiao, E. Bergseng, O. Molberg, J. Xia, B. Fleckenstein, C. Khosla, and L. M. Sollid
Antigen Presentation to Celiac Lesion-Derived T Cells of a 33-Mer Gliadin Peptide Naturally Formed by Gastrointestinal Digestion
J. Immunol.,
August 1, 2004;
173(3):
1757 - 1762.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Fleckenstein, S.-W. Qiao, M. R. Larsen, G. Jung, P. Roepstorff, and L. M. Sollid
Molecular Characterization of Covalent Complexes between Tissue Transglutaminase and Gliadin Peptides
J. Biol. Chem.,
April 23, 2004;
279(17):
17607 - 17616.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-Y. Kim, H. Quarsten, E. Bergseng, C. Khosla, and L. M. Sollid
Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease
PNAS,
March 23, 2004;
101(12):
4175 - 4179.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W Dieterich, D Trapp, B Esslinger, M Leidenberger, J Piper, E Hahn, and D Schuppan
Autoantibodies of patients with coeliac disease are insufficient to block tissue transglutaminase activity
Gut,
November 1, 2003;
52(11):
1562 - 1566.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Orru, I. Caputo, A. D'Amato, M. Ruoppolo, and C. Esposito
Proteomics Identification of Acyl-acceptor and Acyl-donor Substrates for Transglutaminase in a Human Intestinal Epithelial Cell Line: IMPLICATIONS FOR CELIAC DISEASE
J. Biol. Chem.,
August 22, 2003;
278(34):
31766 - 31773.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Parrot, P. C. Huang, and C. Khosla
Circular Dichroism and Nuclear Magnetic Resonance Spectroscopic Analysis of Immunogenic Gluten Peptides and Their Analogs
J. Biol. Chem.,
November 15, 2002;
277(47):
45572 - 45578.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|